XVIII, lesson 35, 1999.McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D . Presented at First International Consultation on Erectile Dysfunction: Sponsored by World Health Organization (WHO), International Consultation on Urological Diseases (ICUD) and Societé Internationale d'Urologie (SIU), Paris, France, July 1–3 1999.Giuliano F, Rampin O . Mean patient age was 40.5 years (range 21–59) in group 1 and 42.5 (range 21–59) in group 2 (Mean patient age was 41.5 years (range 21–59). They know everything about the study and were satisfy with it. Padma-Nathan H, Shabsigh R . Dula E, Keating W, Siami PF, Edmonds A, O'neil J, Buttler S . Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. Bradley KC, Meisel R . Jenkins RB, Groh RH . This is because rather than induce an erection (as Viagra can); cabergoline has been shown to improve libido, orgasm and ejaculation (which Viagra has not).Cabergoline is from the dopaminergic family of drugs that increase the level of dopamine and also decreases the levels of the hormone prolactin. Impotence. Heaton JP . In the meantime, to ensure continued support, we are displaying the site without styles The five separate response domains, erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction, were also used in the assessment of efficacy. Behavioral studies on LEK-8804, a new ergoline derivative with potent 5-HT1A receptor agonist and 5-HT2 receptor antagonist activity. Ferrari F, Ottani A, Giuliani D . Sildenafil Study Group. AUA Update Series, vol. Cabergoline. The patients had to be in a stable relationship with his wife for at least the previous 6 months.Exclusion criteria included penile anatomical defects; a primary diagnosis of another sexual disorder; use of psychotropic and antidepressant medication and serious relationship problems; poorly controlled diabetes mellitus; uncontrolled congestive or ischemic heart disease, or renal or liver impairment, a history of alcohol or drug abuse; spinal cord injury; history of prostate cancer, neurological disorders that cause ED, and those unlikely to be available for follow-up.All patients underwent preliminary assessment, including a medical and sexual history, physical examination, structured interview diagnostic of mental and physical disorders, self-administered International Index of Erectile Function (IIEF), a 15-question, validated measure of EDWhen indicated, other tests were used to establish the diagnosis of vasculogenic and neurogenic ED, including penile color duplex Doppler ultrasonography before and after intracavernosal injection of 20-Of 430 ‘nonresponders’ 402 met inclusion and exclusion criteria and agree to participate in the study.The patients were randomly assigned to either of two groups of subjects. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. Lee HS, Song DH, Kim CH, Choi HK . Rabey JM, Nissipeanu P, Inzelberg R, Korczyn AD . Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. chills. Cabergoline; a review of its efficacy in the treatment of Parkinson's disease. All patients initially suffered from libido impairment, with 10 suffering from reduced sexual potency and 6 were infertile.